RESUMO
OBJECTIVE: To further characterize clinical characteristics, etiologic factors, associated disorders, and treatment of palmoplantar pustulosis (PPP). PATIENTS AND METHODS: We conducted a retrospective review of patients with PPP at Mayo Clinic between January 1, 1996, and December 31, 2013. RESULTS: Of 215 patients with PPP identified, 179 (83%) were female, and the mean age at onset was 45.3 years. Most patients (n=165, 77%) were current or former smokers. At diagnosis, 15 patients (7%) had an anxiety diagnosis and 9 (4%) had an infection. Nineteen cases (9%) were drug induced. Comorbid conditions included thyroid disease in 18 patients (8%), gluten sensitivity in 3 (1%), and type 2 diabetes mellitus in 21 (10%). In all, 194 patients (90%) received topical corticosteroids, 55 (26%) received phototherapy, and 54 (25%) received systemic agents. CONCLUSION: More than three-fourths of the patients in this study had a history of smoking, which is considered a triggering or aggravating factor for PPP. Regarding comorbid conditions, gluten sensitivity and thyroid disease were found less frequently than previously reported in the literature. Treatment regimens and responses in this cohort varied considerably.
Assuntos
Infecção Focal/epidemiologia , Psoríase , Fumar/epidemiologia , Estresse Psicológico/epidemiologia , Fator de Necrose Tumoral alfa/efeitos adversos , Síndrome de Hiperostose Adquirida/epidemiologia , Administração Tópica , Corticosteroides/administração & dosagem , Adulto , Idade de Início , Comorbidade , Diabetes Mellitus Tipo 2/epidemiologia , Feminino , Infecção Focal/complicações , Hipersensibilidade Alimentar/epidemiologia , Glutens/efeitos adversos , Glutens/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Minnesota/epidemiologia , Fototerapia , Psoríase/diagnóstico , Psoríase/epidemiologia , Psoríase/etiologia , Psoríase/terapia , Estudos Retrospectivos , Distribuição por Sexo , Fumar/efeitos adversos , Estresse Psicológico/complicações , Doenças da Glândula Tireoide/epidemiologia , Fator de Necrose Tumoral alfa/uso terapêutico , Adulto JovemRESUMO
Twenty patients with palmoplantar pustulosis (PPP) were treated with topical PUVA, oral etretinate (Re), or combined PUVA and etretinate (Re-PUVA). Re and Re-PUVA treated sites improved and/or cleared more rapidly than PUVA treated sites. Complete clearance was observed in six of ten sites treated with Re-PUVA, two of ten with Re, and one of ten sites with PUVA within 12 weeks. UVA-control sites failed to be cleared within 12 weeks. Remission periods after stopping the treatment were 1.5 +/- 0.5 weeks (n = 2) with Re, 10.5 +/- 11.4 weeks (n = 6) with Re-PUVA, and one year (n = 1) with PUVA. These results overall suggested that Re-PUVA is the most effective treatment for PPP. Tonsillar focal infection (TFI) and dental focal infection (DFI) were found in 6/20 and 17/20 patients, respectively. However, the presence of focal infection (FI), TFI and/or DFI, did not appear to interfere with the therapeutic activities of Re and/or PUVA, because the complete clearance rates and remission periods in FI(+) patients were comparable with those in FI(-) patients.